期刊
TRENDS IN IMMUNOLOGY
卷 36, 期 4, 页码 265-276出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2015.02.008
关键词
PD-1; PD-L1; T cell exhaustion; immunotherapy; cancer; chronic infection
类别
资金
- National Institutes of Health [AI082630, AI05343, AI112521]
- Robertson Foundation/Cancer Research Institute Irvington Fellowship
Inhibitors of the Programmed Cell Death 1: Programmed Cell Death 1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell exhaustion, have been recently shown to be effective for treatment of different cancers. However, clinical responses are mixed, highlighting the need to better understand the mechanisms of action of PD1:PD-L1, the role of this pathway in immunity to different tumors, and the molecular and cellular effects of PD-1 blockade. Here, we review the molecular regulation of T cell exhaustion, placing recent findings on PD-1 blockade therapies in cancer in the context of the broader understanding of the roles of the PD-1:PD-L1 pathway in T cell exhaustion during chronic infection. We discuss the current understanding of the mechanisms involved in reversing T cell exhaustion, and outline critical areas of focus for future research, both basic and clinical.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据